vs

Side-by-side financial comparison of SIMMONS FIRST NATIONAL CORP (SFNC) and Tarsus Pharmaceuticals, Inc. (TARS). Click either name above to swap in a different company.

SIMMONS FIRST NATIONAL CORP is the larger business by last-quarter revenue ($197.3M vs $151.7M, roughly 1.3× Tarsus Pharmaceuticals, Inc.). On growth, Tarsus Pharmaceuticals, Inc. posted the faster year-over-year revenue change (128.4% vs 19.6%). SIMMONS FIRST NATIONAL CORP produced more free cash flow last quarter ($411.4M vs $13.0M). Over the past eight quarters, Tarsus Pharmaceuticals, Inc.'s revenue compounded faster (134.4% CAGR vs 0.6%).

Simmons Bank is a bank with operations in Arkansas, Kansas, Missouri, Oklahoma, Tennessee, and Texas. It is the primary subsidiary of Simmons First National Corporation, a bank holding company.

Tarsus Pharmaceuticals, Inc. is a late-stage clinical biopharmaceutical company focused on developing and commercializing innovative therapeutic candidates for unmet medical needs in ophthalmology, dermatology, and other specialty care areas. It operates primarily in the United States, with lead product candidates targeting common, underdiagnosed conditions including demodex blepharitis and rosacea.

SFNC vs TARS — Head-to-Head

Bigger by revenue
SFNC
SFNC
1.3× larger
SFNC
$197.3M
$151.7M
TARS
Growing faster (revenue YoY)
TARS
TARS
+108.8% gap
TARS
128.4%
19.6%
SFNC
More free cash flow
SFNC
SFNC
$398.4M more FCF
SFNC
$411.4M
$13.0M
TARS
Faster 2-yr revenue CAGR
TARS
TARS
Annualised
TARS
134.4%
0.6%
SFNC

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
SFNC
SFNC
TARS
TARS
Revenue
$197.3M
$151.7M
Net Profit
$-8.4M
Gross Margin
Operating Margin
-5.3%
Net Margin
-5.5%
Revenue YoY
19.6%
128.4%
Net Profit YoY
63.8%
EPS (diluted)
$0.36
$-0.17

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
SFNC
SFNC
TARS
TARS
Q4 25
$197.3M
$151.7M
Q3 25
$186.7M
$118.7M
Q2 25
$214.2M
$102.7M
Q1 25
$209.6M
$78.3M
Q4 24
$208.5M
$66.4M
Q3 24
$174.8M
$48.1M
Q2 24
$197.2M
$40.8M
Q1 24
$195.1M
$27.6M
Net Profit
SFNC
SFNC
TARS
TARS
Q4 25
$-8.4M
Q3 25
$-562.8M
$-12.6M
Q2 25
$54.8M
$-20.3M
Q1 25
$32.4M
$-25.1M
Q4 24
$-23.1M
Q3 24
$24.7M
$-23.4M
Q2 24
$40.8M
$-33.3M
Q1 24
$38.9M
$-35.7M
Operating Margin
SFNC
SFNC
TARS
TARS
Q4 25
-5.3%
Q3 25
-12.2%
Q2 25
-21.6%
Q1 25
-33.5%
Q4 24
-36.8%
Q3 24
-52.3%
Q2 24
-81.6%
Q1 24
-136.5%
Net Margin
SFNC
SFNC
TARS
TARS
Q4 25
-5.5%
Q3 25
-301.5%
-10.6%
Q2 25
25.6%
-19.8%
Q1 25
15.5%
-32.1%
Q4 24
-34.8%
Q3 24
14.1%
-48.7%
Q2 24
20.7%
-81.6%
Q1 24
19.9%
-129.4%
EPS (diluted)
SFNC
SFNC
TARS
TARS
Q4 25
$0.36
$-0.17
Q3 25
$-4.00
$-0.30
Q2 25
$0.43
$-0.48
Q1 25
$0.26
$-0.64
Q4 24
$0.38
$-0.57
Q3 24
$0.20
$-0.61
Q2 24
$0.32
$-0.88
Q1 24
$0.31
$-1.01

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
SFNC
SFNC
TARS
TARS
Cash + ST InvestmentsLiquidity on hand
$417.3M
Total DebtLower is stronger
$620.0M
$72.4M
Stockholders' EquityBook value
$3.4B
$343.4M
Total Assets
$24.5B
$562.2M
Debt / EquityLower = less leverage
0.18×
0.21×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
SFNC
SFNC
TARS
TARS
Q4 25
$417.3M
Q3 25
$401.8M
Q2 25
$381.1M
Q1 25
$407.9M
Q4 24
$291.4M
Q3 24
$317.0M
Q2 24
$323.6M
Q1 24
$298.5M
Total Debt
SFNC
SFNC
TARS
TARS
Q4 25
$620.0M
$72.4M
Q3 25
$667.8M
$72.3M
Q2 25
$1.0B
$72.1M
Q1 25
$1.3B
$72.0M
Q4 24
$1.1B
$71.8M
Q3 24
$1.4B
$71.7M
Q2 24
$1.7B
$71.6M
Q1 24
$1.2B
$29.9M
Stockholders' Equity
SFNC
SFNC
TARS
TARS
Q4 25
$3.4B
$343.4M
Q3 25
$3.4B
$335.1M
Q2 25
$3.5B
$332.6M
Q1 25
$3.5B
$342.5M
Q4 24
$3.5B
$224.5M
Q3 24
$3.5B
$237.5M
Q2 24
$3.5B
$252.2M
Q1 24
$3.4B
$275.2M
Total Assets
SFNC
SFNC
TARS
TARS
Q4 25
$24.5B
$562.2M
Q3 25
$24.2B
$534.6M
Q2 25
$26.7B
$495.0M
Q1 25
$26.8B
$500.8M
Q4 24
$26.9B
$377.0M
Q3 24
$27.3B
$376.3M
Q2 24
$27.4B
$376.8M
Q1 24
$27.4B
$349.3M
Debt / Equity
SFNC
SFNC
TARS
TARS
Q4 25
0.18×
0.21×
Q3 25
0.20×
0.22×
Q2 25
0.28×
0.22×
Q1 25
0.35×
0.21×
Q4 24
0.32×
0.32×
Q3 24
0.40×
0.30×
Q2 24
0.50×
0.28×
Q1 24
0.36×
0.11×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
SFNC
SFNC
TARS
TARS
Operating Cash FlowLast quarter
$449.5M
$19.3M
Free Cash FlowOCF − Capex
$411.4M
$13.0M
FCF MarginFCF / Revenue
208.5%
8.6%
Capex IntensityCapex / Revenue
19.3%
4.2%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$717.0M
$-22.3M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
SFNC
SFNC
TARS
TARS
Q4 25
$449.5M
$19.3M
Q3 25
$223.4M
$18.3M
Q2 25
$77.6M
$-29.4M
Q1 25
$32.8M
$-20.7M
Q4 24
$425.9M
$-22.2M
Q3 24
$199.4M
$-8.7M
Q2 24
$86.1M
$-14.4M
Q1 24
$57.6M
$-37.8M
Free Cash Flow
SFNC
SFNC
TARS
TARS
Q4 25
$411.4M
$13.0M
Q3 25
$216.7M
$16.3M
Q2 25
$66.3M
$-30.4M
Q1 25
$22.6M
$-21.2M
Q4 24
$380.4M
$-22.3M
Q3 24
$187.7M
$-8.9M
Q2 24
$72.7M
$-15.4M
Q1 24
$47.7M
$-38.0M
FCF Margin
SFNC
SFNC
TARS
TARS
Q4 25
208.5%
8.6%
Q3 25
116.1%
13.8%
Q2 25
31.0%
-29.6%
Q1 25
10.8%
-27.1%
Q4 24
182.5%
-33.5%
Q3 24
107.4%
-18.6%
Q2 24
36.9%
-37.8%
Q1 24
24.5%
-137.5%
Capex Intensity
SFNC
SFNC
TARS
TARS
Q4 25
19.3%
4.2%
Q3 25
3.6%
1.6%
Q2 25
5.3%
1.0%
Q1 25
4.8%
0.8%
Q4 24
21.8%
0.1%
Q3 24
6.7%
0.6%
Q2 24
6.8%
2.5%
Q1 24
5.0%
0.6%
Cash Conversion
SFNC
SFNC
TARS
TARS
Q4 25
Q3 25
Q2 25
1.42×
Q1 25
1.01×
Q4 24
Q3 24
8.06×
Q2 24
2.11×
Q1 24
1.48×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons